Trials / Completed
CompletedNCT05719805
A Study to Evaluate the Effects of Mavacamten in Healthy Participants
An Open-label, Randomized, Single-dose, 2-way Crossover Study to Establish Bioequivalence of 1 × 15-mg Mavacamten Capsule to 3 × 5-mg Mavacamten Capsules in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the effect between two different single doses of mavamten in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavacamten | Specified dose on specified days |
Timeline
- Start date
- 2023-02-20
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
- First posted
- 2023-02-09
- Last updated
- 2023-10-12
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05719805. Inclusion in this directory is not an endorsement.